Veru Inc.
VERUVeru Inc. in brief
Veru Inc. is a listed company in the Biotechnology industry, based in Miami, Florida, USA. Its market value was $41 M on 9 October 2026, which makes it the 21,918th largest listed company in the world and the 3,937th largest in the USA on this site. Mitchell Shuster Steiner is its chief executive. Its shares trade under the symbol VERU (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Veru Inc.
Veru is a is an Oncology Biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The company annual revenue is 50 million USD and 386 employee as on 2020. The headquarters is in USA.
Veru Inc. timeline
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- ✎Renamed Veru Inc.Formerly Female Health Co.
- 2021
- 💰Record revenue of $61 millionFY2021, the highest of the 7 years on record.
Events of Veru Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,149 (Jan 2020) · #2,610 (Jan 2021) · #3,054 (Jan 2022) · #2,820 (Dec 2022) · #4,137 (Jul 2023) · #3,696 (Jan 2024) · #2,189 (Mar 2026) · #3,753 (Aug 2026) · #3,913 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 2.3×
- Free cash flow yield
- -72.8%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -124.0%
- Liabilities / assets
- 38.5%
- Payout ratio
- 262.5%
- Revenue growth
- +3.6%
- R&D / revenue
- 75.7%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | — | — | $-25M | $-23M | — |
| Sep 2024 | $17M | +3.6% | $-36M | $-38M | -223.8% |
| Sep 2023 | $16M | -58.6% | $-94M | $-93M | -571.5% |
| Sep 2022 | $39M | -35.8% | $-83M | $-84M | -213.6% |
| Sep 2021 | $61M | +43.8% | $13M | $7M | 12.1% |
| Sep 2020 | $43M | +33.9% | $-15M | $-19M | -44.5% |
| Sep 2019 | $32M | +100.5% | $-6M | $-12M | -37.8% |
| Sep 2018 | $16M | — | $-21M | $-24M | -150.9% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Sep 2025 | $-30M | $0M | $-30M | — | — |
| Sep 2024 | $-22M | $0M | $-22M | — | — |
| Sep 2023 | $-88M | $1M | $-89M | $-1.10 | — |
| Sep 2022 | $-48M | $1M | $-48M | $-1.05 | — |
| Sep 2021 | $-16M | $0M | $-16M | $0.09 | — |
| Sep 2020 | $-2M | $0M | $-2M | $-0.28 | — |
| Sep 2019 | $-5M | $0M | $-6M | $-0.19 | — |
| Sep 2018 | $-12M | $0M | $-12M | $-0.44 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Sep 8, 20268-KCurrent reportOther events
- Aug 10, 202610-QQuarterly report · period to Jun 2026
- Aug 10, 20268-KCurrent reportResults of operations
- Jul 2, 20268-KCurrent reportMaterial agreement
- Jun 4, 20268-KCurrent reportOther events
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
- Mar 13, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Feb 11, 202610-QQuarterly report · period to Dec 2025
- Feb 11, 20268-KCurrent reportResults of operations
- Jan 28, 2026DEF 14AProxy statement
- Dec 17, 202510-KAnnual report · period to Sep 2025
Official filings of Veru Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-25 M
- Net income
- $-23 M
For year ending September-2025 · source: SEC filing
Balance sheet
- Total assets
- $30 M
- Total liabilities
- $12 M
- Total equity
- $18 M
As of September-2025
Top 56 institutional investors in Veru Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 690,105 | -8,334 (-1.19%) | 4.05% | $2 M | Nov 13, 2026 |
| 2 | Renaissance Technologies LLC | 207,450 | +43,000 (+26.15%) | 1.22% | $1 M | Nov 12, 2026 |
| 3 | Oppenheimer & Co Inc | 196,547 | -14,296 (-6.78%) | 1.15% | $1 M | Oct 26, 2026 |
| 4 | Geode Capital Management, LLC | 194,231 | +39,155 (+25.25%) | 1.14% | $1 M | Nov 6, 2026 |
| 5 | BlackRock, Inc. | 164,802 | -2,282 (-1.37%) | 0.97% | $0 M | Nov 13, 2026 |
| 6 | Summit Financial, LLC | 140,955 | -910 (-0.64%) | 0.83% | $0 M | Nov 12, 2026 |
| 7 | Gsa Capital Partners LLP | 129,431 | -27,905 (-17.74%) | 0.76% | $0 M | Nov 16, 2026 |
| 8 | Schonfeld Strategic Advisors LLC | 88,798 | New | 0.52% | $0 M | Nov 16, 2026 |
| 9 | Raymond James Financial Inc | 81,872 | -3,097 (-3.64%) | 0.48% | $0 M | Nov 12, 2026 |
| 10 | Vanguard Fiduciary Trust Co | 81,230 | 0 (0.00%) | 0.48% | $0 M | Nov 13, 2026 |
| 11 | Choreo, LLC | 74,813 | 0 (0.00%) | 0.44% | $0 M | Oct 28, 2026 |
| 12 | NewEdge Advisors, LLC | 60,719 | -9,720 (-13.80%) | 0.36% | $0 M | Nov 13, 2026 |
| 13 | Blair William & Co/il | 60,000 | +2,000 (+3.45%) | 0.35% | $0 M | Nov 10, 2026 |
| 14 | State Street Corp | 55,004 | 0 (0.00%) | 0.32% | $0 M | Nov 12, 2026 |
| 15 | Group One Trading LLC | 54,955 | New | 0.32% | $0 M | Nov 10, 2026 |
| 16 | Two Sigma Investments, LP | 40,374 | New | 0.24% | $0 M | Nov 16, 2026 |
| 17 | ADAR1 Capital Management, LLC | 35,000 | 0 (0.00%) | 0.21% | $0 M | Nov 16, 2026 |
| 18 | Jane Street Group, LLC | 34,177 | -93,676 (-73.27%) | 0.20% | $0 M | Nov 12, 2026 |
| 19 | Northern Trust Corp | 29,809 | -46 (-0.15%) | 0.17% | $0 M | Nov 16, 2026 |
| 20 | Price T Rowe Associates Inc /MD/ | 24,765 | 0 (0.00%) | 0.15% | $0 M | Nov 16, 2026 |
| 21 | Quantinno Capital Management LP | 20,000 | 0 (0.00%) | 0.12% | $0 M | Nov 13, 2026 |
| 22 | Susquehanna International Group, LLP | 19,872 | +7,275 (+57.75%) | 0.12% | $0 M | Nov 16, 2026 |
| 23 | XTX Topco Ltd | 19,196 | New | 0.11% | $0 M | Nov 16, 2026 |
| 24 | Osaic Holdings, Inc. | 16,101 | -152 (-0.94%) | 0.09% | $0 M | Nov 12, 2026 |
| 25 | Morgan Stanley | 12,634 | +5,972 (+89.64%) | 0.07% | $0 M | Nov 13, 2026 |
Show all 56: investors 26 to 56
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Integrated Wealth Concepts LLC | 12,290 | +25 (+0.20%) | 0.07% | $0 M | Nov 17, 2026 |
| 27 | Axq Capital, LP | 10,756 | New | 0.06% | $0 M | Nov 12, 2026 |
| 28 | Northwestern Mutual Wealth Management Co | 10,000 | 0 (0.00%) | 0.06% | $0 M | Nov 13, 2026 |
| 29 | Prime Capital Investment Advisors, LLC | 10,000 | 0 (0.00%) | 0.06% | $0 M | Oct 20, 2026 |
| 30 | Allworth Financial LP | 7,817 | 0 (0.00%) | 0.05% | $0 M | Nov 17, 2026 |
| 31 | Vanguard Global Advisers, LLC | 5,821 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 32 | UBS Group AG | 3,612 | +3,530 (+4304.88%) | 0.02% | $0 M | Nov 10, 2026 |
| 33 | Tower Research Capital LLC (TRC) | 1,842 | +100 (+5.74%) | 0.01% | $0 M | Nov 16, 2026 |
| 34 | Jpmorgan Chase & Co | 1,249 | +876 (+234.85%) | 0.01% | $0 M | Nov 12, 2026 |
| 35 | Chung Wu Investment Group, LLC | 1,000 | 0 (0.00%) | 0.01% | $0 M | Nov 3, 2026 |
| 36 | Strategic Investment Solutions, Inc. /IL | 900 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 37 | Wells Fargo & Company/mn | 750 | -6,235 (-89.26%) | 0.00% | $0 M | Nov 16, 2026 |
| 38 | Quent Capital, LLC | 688 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 39 | Rossby Financial, LCC | 600 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 40 | SBI Securities Co., Ltd. | 418 | +3 (+0.72%) | 0.00% | $0 M | Oct 22, 2026 |
| 41 | Signaturefd, LLC | 300 | 0 (0.00%) | 0.00% | $0 M | Oct 23, 2026 |
| 42 | Axiom Investment Management LLC | 250 | 0 (0.00%) | 0.00% | $0 M | Nov 3, 2026 |
| 43 | Caitong International Asset Management Co., Ltd | 228 | -1,128 (-83.19%) | 0.00% | $0 M | Oct 29, 2026 |
| 44 | Harbour Investments, Inc. | 200 | -5 (-2.44%) | 0.00% | $0 M | Nov 9, 2026 |
| 45 | Rockefeller Capital Management L.P. | 200 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 46 | PlanVest Financial, Inc | 174 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 47 | Farther Finance Advisors, LLC | 130 | New | 0.00% | $0 M | Oct 8, 2026 |
| 48 | Trust Co Of Toledo NA /oh/ | 100 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 49 | Lodestone Wealth Management LLC | 100 | 0 (0.00%) | 0.00% | $0 M | Oct 14, 2026 |
| 50 | Marshall & Sterling Wealth Advisors Inc. | 95 | 0 (0.00%) | 0.00% | $0 M | Oct 28, 2026 |
| 51 | Jones Financial Companies Lllp | 60 | -6 (-9.09%) | 0.00% | $0 M | Nov 13, 2026 |
| 52 | Robinhood Markets, Inc. | 26 | — | 0.00% | $0 M | Nov 18, 2026 |
| 53 | NFSG Corp | 20 | 0 (0.00%) | 0.00% | $0 M | Oct 15, 2026 |
| 54 | Ameritas Advisory Services, LLC | 15 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 55 | BNP Paribas Financial Markets | 7 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 56 | Danske Bank A/s | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
Mutual funds holding Veru Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 531,940 | $2 M | 3.1% | <0.01% | +40% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 158,165 | $0 M | 0.93% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 91,900 | $0 M | 0.54% | <0.01% | +18% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 49,574 | $0 M | 0.29% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 23,036 | $0 M | 0.14% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 20,969 | $0 M | 0.12% | <0.01% | +12% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 8,334 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 8,519 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 6,500 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 3,344 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Veru Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | K. Gary BarnetteChief Scientific Officer | Buy | +1,800 | $2.690 | $5 K | 2,300 | Form 4 |
| filed | Michael L. RankowitzDirector | Buy | +54,721 | $0.580 | $32 K | 250,000 | Form 4 |
| filed | Michael L. RankowitzDirector | Buy | +95,279 | $0.550 | $52 K | 195,279 | Form 4 |
| filed | Harry FischChief Corporate Officer, Director | Buy | +4,000 | $1.250 | $5 K | 774,736 | Form 4 |
| filed | K. Gary BarnetteChief Scientific Officer | Buy | +5,000 | $1.340 | $7 K | 5,000 | Form 4 |
| filed | Mitchell Shuster SteinerPresident and CEO, Director | Sell | -63,379 | $1.230 | $78 K | 6.94 M | Form 4 |
| filed | Mitchell Shuster SteinerPresident and CEO, Director | Sell | -300 | $1.350 | $405 | 7.01 M | Form 4 |
| filed | Mitchell Shuster SteinerPresident and CEO, Director | Sell | -6,504 | $1.390 | $9 K | 7.01 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Veru Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Bankruptcy filing: (8-K)
| Dividend, quarter | Per share | |
|---|---|---|
| Q1 2014 | $0.070 | |
| Q4 2013 | $0.140 | |
| Q4 2013 | $0.070 | |
| Q1 2013 | $0.070 | |
| Q4 2012 | $0.120 | |
| Q1 2012 | $0.060 | |
| Q4 2011 | $0.100 |
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q3 2015 | Q4 2015 | $0M |
| Q2 2015 | Q3 2015 | $0M |
| Q3 2014 | Q4 2014 | $0.5M |
| Q2 2014 | Q3 2014 | $0.2M |
| Q3 2013 | Q4 2013 | $0M |
| Q2 2013 | Q3 2013 | $0M |
| Q1 2013 | Q2 2013 | $0.2M |
| Q4 2012 | Q1 2013 | $0.2M |
| Q3 2012 | Q4 2012 | $0.2M |
| Q2 2012 | Q3 2012 | $0.1M |
| Q1 2012 | Q2 2012 | $0M |
| Q4 2011 | Q1 2012 | $0M |
| Q3 2011 | Q4 2011 | $0M |
| Q2 2011 | Q3 2011 | $0M |
| Q1 2011 | Q2 2012 | $0M |
| Q4 2010 | Q1 2012 | $0M |
Trading halts
- 2026-06-04 16:14 UTC, code LUDP, resumed 16:24 UTC
- 2025-08-08 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 660 shares at $2.42
- : 82 shares at $2.55
- : 87 shares at $2.51
- : 506 shares at $2.41
- : 779 shares at $2.39
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Veru Inc. scorecard#
Passes 2 of the 10 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 9, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median2.2×Price to book 2.2× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-72.8%Free cash flow is -72.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$23 M-$23 M in fiscal 2025 against -$19 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$23 MNet income -$23 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-89.8%-89.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.43 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Veru Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Sep 30, 2025 | FY 2024to Sep 30, 2024 | FY 2023to Sep 30, 2023 | FY 2022to Sep 30, 2022 | FY 2021to Sep 30, 2021 | FY 2020to Sep 30, 2020 | FY 2019to Sep 30, 2019 | FY 2018to Sep 30, 2018 | FY 2017to Sep 30, 2017 | FY 2016to Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | 17+3.6%100% | 16−58.6%100% | 39−35.8%100% | 61+43.8%100% | 43+33.9%100% | 32+100%100% | 16+16.2%100% | 14−38.3%100% | 22—100% | |
| Cost of revenue | — | 11+26.4%65.3% | 8.7−0.4%53.6% | 8.8−34.3%22.3% | 13+12.9%21.8% | 12+16.3%27.7% | 10+43.1%31.9% | 7.1r7.1+6.9%44.7% | 6.6−24.4%48.6% | 8.8—39.7% | |
| Gross profit | — | 5.9−22.6%34.7% | 7.6−75.3%46.4% | 31−36.2%77.7% | 48+55.7%78.2% | 31+42.2%72.3% | 22+147%68.1% | 8.8r8.8+25.0%55.3% | 7.0−47.4%51.4% | 13—60.3% | |
| Research and development | 16+22.0%— | 13r13−75.0%75.7% | 51r51−27.8%314% | 71r71+117%180% | 33+93.1%53.4% | 17+23.2%39.8% | 14+26.7%43.2% | 11+253%68.4% | 3.1r3.5+2995%22.5% | 0.1—0.4% | |
| Selling, general and administrative | — | 31−35.1%185% | 48+11.3%295% | 43r43+109%110% | 21+42.6%33.7% | 14+1.0%34.0% | 14−3.1%45.1% | 15r15+28.7%93.3% | 12r11+32.8%84.2% | 8.7—39.1% | |
| General and administrative | 20−19.0%— | 25—146% | — | — | — | — | — | — | — | — | |
| Operating expenses | 36−5.0%— | 37r44−65.1%221% | 107r107−6.1%657% | 114r114+114%290% | 53+69.8%87.1% | 31r46+11.9%73.8% | 28−5.2%88.3% | 30r30+91.1%187% | 16+50.2%114% | 10—46.7% | |
| Operating income | −25—— | −36r−37—−214% | −94r−94—−575% | −83r−83−744%−212% | 13—21.2% | −15—−34.6% | −6.4—−20.2% | −21—−132% | −8.5−381%−62.2% | 3.0—13.6% | |
| Interest expense and finance costs | — | 0.6−75.0%3.6% | 2.4−44.4%14.9% | 4.4−10.6%11.1% | 4.9+5.7%8.0% | 4.6−1.8%10.9% | 4.7+59.5%14.8% | 3.0—18.6% | — | — | |
| Other non-operating income (expense) | 9.1+898%— | 0.9r−0.2−18.1%5.4% | 1.1—6.8% | −0.3—−0.8% | −8.7—−14.2% | −5.3—−12.5% | −5.9—−18.5% | −2.2—−13.9% | −0.1—−0.8% | −0.2—−0.9% | |
| Income before tax | — | — | −93r−93—−569% | −84r−84−2065%−213% | 4.3—7.0% | −20—−47.1% | −12—−38.7% | −23—−145% | −8.6−406%−63.0% | 2.8—12.7% | |
| Income tax | 0—— | 0r0.7−100%0.0% | 0.5+103%2.9% | 0.2—0.6% | −3.1—−5.1% | −1.1—−2.5% | −0.3−135%−1.0% | 0.9—5.5% | −2.0−181%−14.6% | 2.5—11.2% | |
| Income from continuing operations | −16—— | −35—−209% | — | — | — | — | — | — | — | — | |
| Income from discontinued operations | −7.0—— | −2.5—−15.1% | — | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | −23—— | −38—−224% | −93r−93—−572% | −84r−84−1237%−214% | 7.4—12.1% | −19—−44.5% | −12—−37.8% | −24—−151% | −6.6−2018%−48.4% | 0.3—1.6% | |
| Earnings per share, basic | -1.55—— | -2.80r-0.28—— | -1.10—— | -1.05−1150%— | 0.10—— | -0.28—— | -0.19—— | -0.44—— | -0.25−2600%— | 0.01—— | |
| Earnings per share, diluted | — | — | -1.10—— | -1.05−1267%— | 0.09—— | -0.28—— | -0.19—— | -0.44—— | -0.25−2600%— | 0.01—— | |
| Shares, weighted average (basic) | 15+8.6%— | 13r135−84.1%— | 85+6.1%— | 80+5.0%— | 76+14.3%— | 67—— | — | — | 35+20.8%— | 29—— | |
| Shares, weighted average (diluted) | — | — | 85+6.1%— | 80−4.4%— | 84+25.5%— | 67+5.4%— | 63+17.6%— | 54+55.5%— | 35+19.8%— | 29—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 16−36.6%52.9% | 25+159%41.2% | 9.6—19.2% | — | — | — | — | 3.8+14.7%7.8% | 3.3+37.4%5.9% | 2.4—6.2% | |
| Receivables | — | 4.0−12.1%6.6% | 4.5+26.9%9.0% | 3.6−59.6%2.6% | 8.8+68.2%4.9% | 5.2+4.1%10.1% | 5.0+26.4%9.4% | 4.0+16.2%8.2% | 3.4r3.6−68.3%6.2% | 11—27.9% | |
| Inventory | — | 4.1−38.1%6.9% | 6.7−22.3%13.4% | 8.6+54.6%6.4% | 5.6−16.9%3.1% | 6.7+83.8%13.0% | 3.6+58.4%6.8% | 2.3−16.8%4.8% | 2.8+11.0%5.0% | 2.5—6.5% | |
| Other current assets | 0.6−26.1%2.0% | 0.8r1.8−26.6%1.3% | 1.1−44.1%2.2% | 2.0+131%1.5% | 0.9−3.4%0.5% | 0.9r1.5−52.2%1.7% | 1.8+60.5%3.4% | 1.1+37.7%2.4% | 0.8r0.7+31.4%1.5% | 0.6—1.6% | |
| Current assets | 19−46.3%63.4% | 35+53.6%58.3% | 23r24−77.9%45.8% | 104r105−31.5%76.8% | 152+462%85.2% | 27+60.7%52.4% | 17+50.3%31.3% | 11+8.6%23.1% | 10−36.8%18.6% | 16r18—42.2% | |
| Property, plant and equipment | 0.4−24.2%1.2% | 0.5r1.3−70.9%0.8% | 1.7+39.4%3.3% | 1.2+100%0.9% | 0.6+89.5%0.3% | 0.3−11.1%0.6% | 0.4−13.0%0.7% | 0.4−27.2%0.8% | 0.6−32.7%1.0% | 0.8—2.1% | |
| Right-of-use (leased) assets | 2.7−15.5%9.2% | 3.3r3.6−25.0%5.4% | 4.3−9.5%8.7% | 4.8+394%3.5% | 1.0−28.3%0.5% | 1.4—2.6% | — | — | — | — | |
| Goodwill | 6.90.0%23.1% | 6.90.0%11.4% | 6.90.0%13.8% | 6.90.0%5.1% | 6.90.0%3.9% | 6.90.0%13.3% | 6.90.0%12.8% | 6.90.0%14.2% | 6.9—12.4% | — | |
| Other intangible assets | — | 0−100%0.0% | 0.0−99.9%0.0% | 4.0−1.8%2.9% | 4.0−29.6%2.3% | 5.8−71.5%11.2% | 20−1.5%37.6% | 20−1.3%42.3% | 21—37.5% | — | |
| Total assets | 30−50.6%100% | 60+20.8%100% | 50r51−63.0%100% | 135r136−24.0%100% | 178+246%100% | 52−3.9%100% | 54+10.7%100% | 48−12.4%100% | 55r55+43.3%100% | 39—100% | |
| Accounts payable | 3.1+38.1%10.5% | 2.3r3.0−82.5%3.7% | 13r15−41.2%25.9% | 22+545%16.3% | 3.4+21.2%1.9% | 2.8−10.0%5.5% | 3.1−3.1%5.8% | 3.2+20.1%6.7% | 2.7+283%4.9% | 0.7—1.8% | |
| Current liabilities | 7.8−34.4%26.1% | 12−33.4%19.6% | 18r20−54.0%35.6% | 39r41+146%28.6% | 16+7.1%8.9% | 15+5.0%28.6% | 14+3.4%26.1% | 14+147%28.0% | 5.5+64.0%9.9% | 3.3—8.7% | |
| Long-term debt | — | — | — | — | — | — | — | 1.8—3.6% | — | — | |
| Lease liabilities (non-current) | 2.4−18.8%7.9% | 2.9r2.9−20.1%4.8% | 3.6−11.2%7.3% | 4.1+571%3.0% | 0.6−38.4%0.3% | 1.0—1.9% | — | — | — | — | |
| Total liabilities | 12−59.1%38.6% | 28−7.4%46.5% | 30r33−42.3%60.7% | 53r55+103%38.8% | 26+20.6%14.5% | 21+0.6%41.6% | 21+12.3%39.7% | 19+176%39.2% | 6.9r6.9+46.8%12.4% | 4.7—12.1% | |
| Retained earnings | −317—−1063% | −295—−488% | −257r−259—−513% | −164r−166—−121% | −82—−45.9% | −89—−173% | −70—−131% | −58—−120% | −34—−61.9% | −28—−71.6% | |
| Shareholders' equity | 18−43.3%61.4% | 32+64.2%53.5% | 20r18−76.2%39.3% | 83r81−46.4%61.2% | 155r152+413%86.7% | 30−6.9%58.4% | 32+9.7%60.3% | 29−39.2%60.8% | 48+42.8%87.6% | 34—87.9% | |
| Total liabilities and equity | 30−50.6%100% | 60+20.8%100% | 50r51−63.0%100% | 135r136−24.0%100% | 178+246%100% | 52−3.9%100% | 54+10.7%100% | 48−12.4%100% | 55r55+43.3%100% | 39—100% | |
| Shares outstanding | 15+0.1%— | 15r146−84.1%— | 92+14.0%— | 81+0.7%— | 80+14.5%— | 70+7.4%— | 65+17.6%— | 55+3.9%— | 53+82.9%— | 29—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.2−43.3%— | 0.3−0.6%1.6% | 0.3—1.7% | — | — | — | — | 0.2−47.1%1.1% | 0.3−21.0%2.4% | 0.4—1.9% | |
| Share-based compensation | 8.1−40.6%— | 14−23.9%80.8% | 18+59.4%110% | 11+123%28.6% | 5.1+90.9%8.2% | 2.6+38.8%6.2% | 1.9+16.3%6.0% | 1.6+117%10.3% | 0.8+51.3%5.5% | 0.5—2.3% | |
| Cash from operating activities | −30—— | −22—−128% | −88—−540% | −48—−121% | −16—−25.4% | −1.9—−4.5% | −5.5—−17.2% | −12−1275%−72.8% | 1.0—7.2% | −1.7—−7.7% | |
| Capital expenditure | −0.0—— | −0.2—−0.9% | −0.7—−4.1% | −0.7—−1.9% | −0.4—−0.6% | −0.1—−0.2% | −0.1—−0.3% | −0.1—−0.3% | −0.1—−1.0% | −0.0—−0.0% | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | — | −0.0r−0.0—−0.3% | — | |
| Cash from investing activities | 25+17096%— | 0.1−97.7%0.9% | 6.3+48.5%38.9% | 4.3−70.8%10.8% | 15—23.9% | −0.1—−0.2% | −0.1—−0.3% | −0.1—−0.3% | −0.1—−0.7% | −0.0—−0.0% | |
| Debt issued | — | 0−100%0.0% | 1.4—8.7% | — | — | — | — | — | — | — | |
| Debt repaid | 0—— | −0.1—−0.8% | −1.3—−7.9% | — | — | — | — | — | — | — | |
| Shares issued | — | — | — | — | 108+707%176% | 13+272%31.5% | 3.6+20.0%11.3% | 3.0—18.9% | — | — | |
| Cash from financing activities | −4.2−111%— | 37+231%218% | 11+940%68.2% | 1.1−99.0%2.7% | 110+1076%179% | 9.3+14.8%21.9% | 8.1−32.7%25.6% | 12—76.1% | — | — | |
| Change in cash | −9.1−160%— | 15—90.6% | −71—−433% | −42−139%−107% | 109+1391%178% | 7.3+188%17.1% | 2.5+426%8.0% | 0.5−46.0%3.0% | 0.9—6.5% | −1.7—−7.8% | |
| Report | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q3 FY2026to Jun 30, 2026 | Q2 FY2026to Mar 31, 2026 | Q1 FY2026to Dec 31, 2025 | Q4 FY2025to Sep 30, 2025 | Q3 FY2025to Jun 30, 2025 | Q2 FY2025to Mar 31, 2025 | Q1 FY2025to Dec 31, 2024 | Q4 FY2024to Sep 30, 2024 | Q3 FY2024to Jun 30, 2024 | Q2 FY2024to Mar 31, 2024 | Q1 FY2024to Dec 31, 2023 | Q4 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | — | 0−100%— | 0−100%— | — | 6.7*+72.4%100% | 4.0—100% | 4.1—100% | 2.1—100% | 3.9*—100% | |
| Cost of revenue | — | — | — | — | — | — | — | — | 4.0*+71.0%59.6% | 2.6—66.2% | 3.5—83.6% | 1.0—46.3% | 2.3*—60.1% | |
| Gross profit | — | — | — | — | — | — | — | — | 2.7*+74.4%40.4% | 1.3—33.8% | 0.7—16.4% | 1.2—53.7% | 1.5*—39.9% | |
| Research and development | 12−26.3%— | 4.4+44.1%— | 3.1−20.0%— | 1.3−76.5%— | 2.9*−11.3%— | 3.0−37.7%— | 3.9+31.7%— | 5.7+245%— | 3.3r3.3*−16.5%49.5% | 4.8r4.9—123% | 3.0r3.0—72.2% | 1.7r1.7—77.5% | 3.9r6.6*—102% | |
| Selling, general and administrative | — | — | — | — | — | 5.0−13.8%— | 5.2−12.5%— | 5.2−21.4%— | 13r7.8*+89.2%193% | 5.8r7.5—147% | 5.9r7.6—143% | 6.7r8.3—311% | 6.8*—175% | |
| General and administrative | 16—— | 3.4−32.9%— | 4.1−21.1%— | 4.1−21.9%— | 4.5*—— | 5.0—— | 5.2—— | 5.2—— | — | — | — | — | — | |
| Operating expenses | 28−26.0%— | 7.7−4.0%— | 7.2−20.6%— | 5.4−50.4%— | 7.5*−21.8%— | 8.0−24.6%— | 9.1+2.3%— | 11+31.7%— | 9.5r11*−11.0%143% | 11r12—269% | 8.9r11—215% | 8.3r10.0—388% | 11r13*—278% | |
| Operating income | −19—— | −7.7—— | −7.2—— | −5.4—— | 1.2*—— | −7.5—— | −8.1—— | −10—— | −9.3r−8.2*—−140% | −11r−11—−267% | −8.9r−9.9—−215% | −7.4r−7.9—−345% | −8.2r−11*—−212% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | 0.2*−18.0%2.6% | 0.1—3.2% | 0.1—3.5% | 0.2—7.7% | 0.2*—5.4% | |
| Other non-operating income (expense) | 5.1−47.8%— | 0.7+225%— | 4.1+1429%— | 0.1−98.9%— | 0.1*−82.7%— | 0.2+8.7%— | 0.3+45.3%— | 8.4—— | 0.8r0.1*+31.9%11.9% | 0.2r0.1—5.2% | 0.2r0.0—4.5% | −0.3r−0.5—−12.9% | 0.6*—15.6% | |
| Income before tax | — | — | — | — | — | — | — | — | — | — | −9.8—−238% | −8.3—−390% | −7.6r−10*—−196% | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0r0.5*−100%0.0% | 0r0.2—0.0% | 0r0.2—0.0% | 0r−0.1—0.0% | 0.6*—14.4% | |
| Income from continuing operations | −14—— | −7.0—— | −3.1—— | −5.3—— | 1.3*—— | −7.3—— | −7.9—— | −1.8—— | −8.5*—−128% | −10—−262% | −8.7—−210% | −7.7—−358% | — | |
| Income from discontinued operations | 0.5—— | 0—— | 0.4—— | 0—— | 0.1*+695%— | −0.0—— | −0.0—— | −7.1—— | 0.0*—0.3% | −0.6—−15.9% | −1.3—−32.0% | −0.6—−28.4% | — | |
| Net income attributable to shareholders | −14—— | −7.0—— | −2.7—— | −5.3—— | 1.5*—— | −7.3—— | −7.9—— | −8.9—— | −8.5*—−128% | −11—−277% | −10—−242% | −8.3—−387% | −8.1r−11*—−211% | |
| Earnings per share, basic | — | -0.30—— | -0.12—— | -0.26—— | — | -0.50—— | -0.54r-0.05—— | -0.61r-0.06—— | — | -0.75r-0.07—— | -0.07—— | -0.08—— | — | |
| Earnings per share, diluted | — | — | — | — | — | — | — | — | — | — | -0.07—— | -0.08—— | — | |
| Shares, weighted average (basic) | 23+57.3%— | 23+57.3%— | 23+57.5%— | 20+38.8%— | — | 15+0.1%— | 15r146−90.0%— | 15r146−85.4%— | — | 15r146—— | 146—— | 101—— | — | |
| Shares, weighted average (diluted) | — | — | — | — | — | — | — | — | — | — | 146—— | 101—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 24—64.5% | 24+59.1%64.5% | 28+37.9%64.1% | 33+24.0%69.4% | 16−36.6%52.9% | 15−48.5%54.9% | 20—61.3% | 27—66.8% | 25+159%41.2% | 29—45.1% | — | — | 9.6—19.2% | |
| Receivables | — | — | — | — | — | — | — | — | 4.0−12.1%6.6% | 1.6—2.5% | 2.8—3.9% | 2.4—3.0% | 4.5—9.0% | |
| Inventory | — | — | — | — | — | — | — | — | 4.1−38.1%6.9% | 4.9—7.6% | 4.8—6.7% | 6.9—8.6% | 6.7—13.4% | |
| Other current assets | 1.4—3.9% | 1.4+21.5%3.9% | 2.6+90.6%6.0% | 1.4−20.5%3.0% | 0.6−26.1%2.0% | 1.2−26.8%4.3% | 1.4−27.9%4.2% | 1.8−20.9%4.5% | 0.8r1.8−26.6%1.3% | 1.6—2.5% | 1.9—2.6% | 2.2—2.8% | 1.1—2.2% | |
| Current assets | 27—73.5% | 27+68.1%73.5% | 33+56.0%77.4% | 37+29.7%77.4% | 19−46.3%63.4% | 16−57.9%59.2% | 21−52.6%65.4% | 28−46.8%71.3% | 35+53.6%58.3% | 38—59.5% | 45—62.9% | 53—66.2% | 23r24—45.8% | |
| Property, plant and equipment | 0.3—0.8% | 0.3−28.8%0.8% | 0.3−27.0%0.7% | 0.3−25.5%0.7% | 0.4−24.2%1.2% | 0.4−73.6%1.4% | 0.4−72.4%1.3% | 0.5−71.0%1.1% | 0.5r1.3−70.9%0.8% | 1.5—2.3% | 1.5—2.1% | 1.6—1.9% | 1.7—3.3% | |
| Right-of-use (leased) assets | 2.3—6.3% | 2.3−18.6%6.3% | 2.5−17.4%5.8% | 2.6−16.4%5.5% | 2.7−15.5%9.2% | 2.9−23.5%10.5% | 3.0−23.9%9.2% | 3.1−24.3%7.9% | 3.3r3.6−25.0%5.4% | 3.8—5.8% | 3.9—5.5% | 4.1—5.1% | 4.3—8.7% | |
| Goodwill | 6.9—18.6% | 6.90.0%18.6% | 6.90.0%16.0% | 6.90.0%14.5% | 6.90.0%23.1% | 6.90.0%25.2% | 6.90.0%21.1% | 6.9−0.3%17.3% | 6.90.0%11.4% | 6.9—10.6% | 6.9—9.6% | 6.9r6.9—8.6% | 6.9—13.8% | |
| Other intangible assets | — | — | — | — | — | — | — | — | 0−100%0.0% | — | — | — | 0.0—0.0% | |
| Total assets | 37—100% | 37+35.5%100% | 43+31.9%100% | 48+19.4%100% | 30−50.6%100% | 27−57.7%100% | 33−54.5%100% | 40−50.6%100% | 60+20.8%100% | 65—100% | 72—100% | 81—100% | 50r51—100% | |
| Accounts payable | 1.7—4.6% | 1.7−32.7%4.6% | 2.1−6.1%4.8% | 1.5−24.0%3.2% | 3.1+38.1%10.5% | 2.5−15.9%9.3% | 2.2−10.5%6.8% | 2.0−81.0%5.0% | 2.3r3.0−82.5%3.7% | 3.0—4.7% | 2.5—3.4% | 11—13.1% | 13r15—25.9% | |
| Current liabilities | 6.2—16.6% | 6.2−7.9%16.6% | 5.4−4.1%12.5% | 7.1+12.3%15.0% | 7.8−34.4%26.1% | 6.7−37.1%24.4% | 5.6−41.3%17.2% | 6.3−61.8%15.9% | 12−33.4%19.6% | 11—16.4% | 9.6—13.3% | 17—20.6% | 18r20—35.6% | |
| Lease liabilities (non-current) | 1.9—5.2% | 1.9−23.7%5.2% | 2.1−21.9%4.8% | 2.2−20.3%4.7% | 2.4−18.8%7.9% | 2.5−18.7%9.1% | 2.6−19.1%8.1% | 2.8−19.7%7.0% | 2.9r2.9−20.1%4.8% | 3.1—4.8% | 3.3—4.5% | 3.5—4.3% | 3.6—7.3% | |
| Total liabilities | 8.7—23.4% | 8.7−27.8%23.4% | 8.3−28.6%19.3% | 10−20.9%22.0% | 12−59.1%38.6% | 12−55.6%43.9% | 12−56.3%35.6% | 13−54.4%33.1% | 28−7.4%46.5% | 27—41.8% | 27—37.0% | 29—36.0% | 30r33—60.7% | |
| Retained earnings | −332—−898% | −332—−898% | −325—−755% | −323—−678% | −317—−1063% | −319—−1166% | −311—−953% | −304—−762% | −295—−488% | −286—−443% | −275—−383% | −265—−329% | −257r−259—−513% | |
| Shareholders' equity | 28—76.6% | 28+84.9%76.6% | 35+65.3%80.7% | 37+39.4%78.0% | 18−43.3%61.4% | 15−59.2%56.1% | 21−53.4%64.4% | 27−48.4%66.9% | 32+64.2%53.5% | 38—58.2% | 45—63.0% | 52—64.0% | 20r18—39.3% | |
| Total liabilities and equity | 37—100% | 37+35.5%100% | 43+31.9%100% | 48+19.4%100% | 30−50.6%100% | 27−57.7%100% | 33−54.5%100% | 40−50.6%100% | 60+20.8%100% | 65—100% | 72—100% | 81—100% | 50r51—100% | |
| Shares outstanding | 17—— | 17+16.4%— | 16−89.1%— | 16−89.0%— | 15+0.1%— | 15−90.0%— | 147+0.1%— | 146+0.0%— | 15r146−84.1%— | 146—— | 146—— | 146—— | 92—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1−40.0%— | 0.0*−3.9%— | 0.0*−3.9%— | 0.0−56.5%— | 0.0*−56.1%— | 0.0*−54.9%— | 0.0*−55.4%— | 0.1−10.1%— | 0.1*−7.2%1.0% | 0.1*—1.6% | 0.1*—1.6% | 0.1—3.4% | 0.1*—1.8% | |
| Share-based compensation | 3.3−66.6%— | 0.6−65.4%— | 0.4−81.9%— | 0.8−71.7%— | 1.5*−52.4%— | 1.7−50.6%— | 2.2−38.8%— | 2.7−21.5%— | 3.2*−31.1%48.5% | 3.4—85.4% | 3.6—87.9% | 3.4—159% | 4.7*—121% | |
| Cash from operating activities | −26—— | −5.5*—— | −8.9*—— | −6.2—— | −5.5*—— | −5.5*—— | −7.7*—— | −11—— | −4.4*—−65.6% | −5.6*—−143% | −5.7*—−137% | −6.0—−281% | −9.5*—−246% | |
| Capital expenditure | 0—— | 0*—— | 0*—— | 0—— | 0*—— | 0*—— | 0*—— | −0.0—— | −0.1*—−0.9% | −0.1*—−1.4% | −0.0*—−1.0% | 0—0.0% | −0.2*—−5.5% | |
| Cash from investing activities | 12−39.0%— | 1.8*+280%— | 3.5*+207%— | 0−100%— | 6.3*+4672%— | 0.5*+756%— | 1.1*—— | 17—— | 0.1*−83.3%2.0% | 0.1*—1.4% | −0.0*—−1.0% | 0—0.0% | 0.8*—20.4% | |
| Debt issued | — | — | — | — | — | — | — | — | 0*—0.0% | — | — | — | 0*—0.0% | |
| Debt repaid | — | — | — | — | 0*—— | 0*—— | 0*—— | 0—— | 0*—0.0% | 0*—0.0% | 0*—0.0% | −0.1—−6.2% | −0.4*—−10.2% | |
| Cash from financing activities | 23—— | −0.1*—— | 0*—— | 23—— | 0*—— | 0*−100%— | 0*—— | −4.2−111%— | 0*−100%0.0% | 0.0*—0.1% | −0.2*—−3.6% | 37—1727% | 2.1*—54.8% | |
| Change in cash | 8.9—— | −3.7*—— | −5.4*—— | 17+917%— | 0.8*—— | −5.0*—— | −6.6*—— | 1.7−94.5%— | −4.2*—−63.6% | −5.6*—−141% | −5.8*—−141% | 31—1446% | −6.6*—−171% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Veru Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Mitchell Steiner | $1.6 M | $1.4 M | $855 K | $3 |
| 2024Mitchell Steiner | $2.0 M | $1.8 M | $926 K | $7 |
| 2023Mitchell Steiner | $4.7 M | −$6.0 M | $1.6 M | $6 |
Source: SEC proxy statement (Form DEF 14A) · as of Sep 30, 2025
Events at Veru Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 2 · Auditor changed 1 · Debt called early 1 · Acquisition or sale completed 1 · Directors and officers 3 · Material agreement 4 · Agreement ended 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 5 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Agreement ended | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Debt called earlyAcquisition or sale completedMaterial agreementAgreement ended | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| Agreement ended | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Shareholder vote | 8-K | |
| Auditor changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Aug 10, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2016 | $23 M | Private placement after listing | $10 to $50 million | 23 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Veru Inc.#
$0 spent on lobbying the US Congress and federal agencies in 2024, most often on budget/appropriations.
- Budget/Appropriations4 reports
Lobbying firms hired in 2024
HUSCH BLACKWELL STRATEGIES
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2024 | $0 | — | 4 |
| 2023 | $170 K | — | 6 |
| 2022 | $410 K | — | 9 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Veru, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2009 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Veru Inc. compares in Biotechnology
- Market cap$41 M · higher than 24% of 726
- Revenue growth3.6% · higher than 48% of 438
- Price / book2.3× · lower than 56% of 534
- FCF yield-72.8% · higher than 15% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Veru Inc.🇺🇸 | $41 M | — | — | +3.6% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 9, 2026
- Annual results:
- For year ending September-2025
- Balance sheet:
- As of September-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Veru Inc.? Verify and update this profile — free
Show Veru Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.